New hope for lung cancer: experimental drug combo enters human trials
Disease control
Not yet recruiting
This study tests a new drug called DXC006 combined with either immunotherapy or chemotherapy in 200 people with small cell lung cancer. The goal is to find the safest dose and see if the combination shrinks tumors or delays cancer growth. Participants must be 18-75 years old and …
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:39 UTC